These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 38339133)

  • 1. Impact of Glucagon-Like Peptide 1 Receptor Agonists on Biochemical Markers of the Initiation of Atherosclerotic Process.
    Hachuła M; Kosowski M; Ryl S; Basiak M; Okopień B
    Int J Mol Sci; 2024 Feb; 25(3):. PubMed ID: 38339133
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of Dulaglutide on Serum Biomarkers of Atherosclerotic Plaque Instability: An Interventional Analysis of Cytokine Profiles in Diabetic Subjects-A Pilot Study.
    Hachuła M; Kosowski M; Basiak M; Okopień B
    Medicina (Kaunas); 2024 May; 60(6):. PubMed ID: 38929525
    [No Abstract]   [Full Text] [Related]  

  • 3. GLP-1 receptor agonists and reduction of cardiometabolic risk: Potential underlying mechanisms.
    Rizzo M; Nikolic D; Patti AM; Mannina C; Montalto G; McAdams BS; Rizvi AA; Cosentino F
    Biochim Biophys Acta Mol Basis Dis; 2018 Sep; 1864(9 Pt B):2814-2821. PubMed ID: 29778663
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Beyond the Cardiovascular Effects of Glucagon-like Peptide-1 Receptor Agonists: Body Slimming and Plaque Stabilization. Are New Statins Born?
    Lecis D; Prandi FR; Barone L; Belli M; Sergi D; Longo S; Muscoli S; Romeo F; Federici M; Lerakis S; Barillà F
    Biomolecules; 2023 Nov; 13(12):. PubMed ID: 38136567
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glucagon-Like Peptide-1 Receptor Agonists and Cardiovascular Risk Reduction in Type 2 Diabetes Mellitus: Is It a Class Effect?
    Li Y; Rosenblit PD
    Curr Cardiol Rep; 2018 Sep; 20(11):113. PubMed ID: 30259238
    [TBL] [Abstract][Full Text] [Related]  

  • 6. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art.
    Nauck MA; Quast DR; Wefers J; Meier JJ
    Mol Metab; 2021 Apr; 46():101102. PubMed ID: 33068776
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The GLP-1 receptor agonist liraglutide inhibits progression of vascular disease via effects on atherogenesis, plaque stability and endothelial function in an ApoE(-/-) mouse model.
    Gaspari T; Welungoda I; Widdop RE; Simpson RW; Dear AE
    Diab Vasc Dis Res; 2013 Jul; 10(4):353-60. PubMed ID: 23673376
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Usefulness of Once-Weekly GLP-1 Receptor Agonist Semaglutide on Glycemic Control in Subjects with Type 2 Diabetes Mellitus: Switching from the Same Class Dulaglutide in a Retrospective Observation Study.
    Kimura T; Kubo M; Takahashi K; Wamata R; Iwamoto Y; Iwamoto H; Katakura Y; Sanada J; Fushimi Y; Shimoda M; Tatsumi F; Nakanishi S; Mune T; Kaku K; Kaneto H
    J Diabetes Res; 2024; 2024():5880589. PubMed ID: 38223524
    [TBL] [Abstract][Full Text] [Related]  

  • 9. GLP-1 receptor agonists in the treatment of type 2 diabetes: role and clinical experience to date.
    Brunton SA; Wysham CH
    Postgrad Med; 2020 Nov; 132(sup2):3-14. PubMed ID: 32815454
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis.
    Yao H; Zhang A; Li D; Wu Y; Wang CZ; Wan JY; Yuan CS
    BMJ; 2024 Jan; 384():e076410. PubMed ID: 38286487
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of tirzepatide on glycaemic control and weight loss compared with other glucagon-like peptide-1 receptor agonists in Japanese patients with type 2 diabetes mellitus.
    Tsukamoto S; Tanaka S; Yamada T; Uneda K; Azushima K; Kinguchi S; Wakui H; Tamura K
    Diabetes Obes Metab; 2024 Jan; 26(1):262-274. PubMed ID: 37828829
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis.
    Htike ZZ; Zaccardi F; Papamargaritis D; Webb DR; Khunti K; Davies MJ
    Diabetes Obes Metab; 2017 Apr; 19(4):524-536. PubMed ID: 27981757
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glucagon-like peptide-1 receptor agonist dulaglutide prevents ox-LDL-induced adhesion of monocytes to human endothelial cells: An implication in the treatment of atherosclerosis.
    Chang W; Zhu F; Zheng H; Zhou Z; Miao P; Zhao L; Mao Z
    Mol Immunol; 2019 Dec; 116():73-79. PubMed ID: 31630078
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of clinical efficacy and safety of weekly glucagon-like peptide-1 receptor agonists dulaglutide and semaglutide in Japanese patients with type 2 diabetes: Randomized, parallel-group, multicentre, open-label trial (COMING study).
    Kimura T; Katakura Y; Shimoda M; Kawasaki F; Yamabe M; Tatsumi F; Matsuki M; Iwamoto Y; Anno T; Fushimi Y; Kamei S; Kimura Y; Nakanishi S; Mune T; Kaku K; Kaneto H;
    Diabetes Obes Metab; 2023 Dec; 25(12):3632-3647. PubMed ID: 37646192
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact on HbA1c and body weight of switching from other GLP-1 receptor agonists to semaglutide: A model-based approach.
    Overgaard RV; Lindberg SØ; Thielke D
    Diabetes Obes Metab; 2019 Jan; 21(1):43-51. PubMed ID: 30047216
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [A new era for glucagon-like peptide-1 receptor agonists].
    Neuville MF; Paquot N; Scheen AJ
    Rev Med Liege; 2023 Jan; 78(1):40-45. PubMed ID: 36634066
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of GLP-1RA Treatment on Adhesion Molecules and Monocyte Chemoattractant Protein-1 in Diabetic Patients with Atherosclerosis.
    Hachuła M; Basiak M; Kosowski M; Okopień B
    Life (Basel); 2024 May; 14(6):. PubMed ID: 38929672
    [TBL] [Abstract][Full Text] [Related]  

  • 18. GLP-1RAs for Ischemic Stroke Prevention in Patients With Type 2 Diabetes Without Established Atherosclerotic Cardiovascular Disease.
    Yang YS; Chen HH; Huang CN; Hsu CY; Hu KC; Kao CH
    Diabetes Care; 2022 May; 45(5):1184-1192. PubMed ID: 35275992
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glucagon-like peptide-1 receptor agonists in type 2 diabetes treatment: are they all the same?
    Gentilella R; Pechtner V; Corcos A; Consoli A
    Diabetes Metab Res Rev; 2019 Jan; 35(1):e3070. PubMed ID: 30156747
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Microvascular effects of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized controlled trials.
    Dicembrini I; Nreu B; Scatena A; Andreozzi F; Sesti G; Mannucci E; Monami M
    Acta Diabetol; 2017 Oct; 54(10):933-941. PubMed ID: 28748377
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.